Definition

A T-cell engaging (TCE) and heavy chain variable domain (VHH)-based nanobody targeting the tumor-associated antigen (TAA) glypican-3 (GPC3; GPC-3) and a T-cell surface antigen, with potential antineoplastic activity. Upon administration, anti-GPC3/TCR nanobody SAR444200 specifically targets and binds to GPC3 expressed on tumor cells and a T-cell surface antigen on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to GPC3-expressing tumor cells, leading to CTL-mediated killing of GPC3-expressing tumor cells. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed in normal, healthy cells. GPC3 plays an important role in tumor cell proliferation in various tumor cell types.